menu
    • menu
    [{"orgOrder":0,"company":"Actelion Pharmaceuticals Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRITON Phase 3b Study Results Presented at the European Society of Cardiology Congress","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Selexipag","moa":"Prostanoid IP receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Actelion Pharmaceuticals Ltd","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Actelion Pharmaceuticals Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Actelion P.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submits NDA for UPTRAVI\u00ae Injection for Intravenous Use to Treat Pulmonary Arterial Hypertension (PAH)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Selexipag","moa":"Prostanoid IP receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Demonstrate the Benefits of Early Use of UPTRAVI in Delaying Disease Progression in a Broad Population of Patients with PAH","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Selexipag","moa":"Prostanoid IP receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic announces USFDA tentative approval for Selexipag for Injection, 1,800 mcg\/vial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Selexipag","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"","highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"13","companyTruncated":"Alembic Ph.."}]

    Find Clinical Drug Pipeline Developments & Deals for Selexipag

    Menu

    Selexipag

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alembic Pharmaceuticals Limited

                            India arrow
                            Formnext Forum
                            Not Confirmed

                            Alembic Pharmaceuticals Limited

                            India arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Selexipag

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Alembic announces USFDA tentative approval for Selexipag for Injection, 1,800 mcg/vial

                            Details : Uptravi-Generic (selexipag) is a prostacyclin receptor agonist small molecule drug candidate, which is indicated for the treatment of pulmonary arterial hypertension.

                            Brand Name : Uptravi-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 14, 2024

                            Lead Product(s) : Selexipag

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Johnson & Johnson Innovative Medicine

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Johnson & Johnson Innovative Medicine

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Selexipag

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            New Data Demonstrate the Benefits of Early Use of UPTRAVI in Delaying Disease Progression in a Broad Populatio...

                            Details : Post-hoc pooled data analysis of PAH patients suggests that targeting the prostacyclin pathway with selexipag within a short timeframe after diagnosis may reduce the risk of disease progression.

                            Brand Name : Uptravi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 30, 2021

                            Lead Product(s) : Selexipag

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Johnson & Johnson Innovative Medicine

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Johnson & Johnson Innovative Medicine

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Selexipag

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Janssen Submits NDA for UPTRAVI® Injection for Intravenous Use to Treat Pulmonary Arterial Hypertension (PAH)

                            Details : UPTRAVI is a selective, prostacyclin IP receptor agonist. Oral UPTRAVI was approved by the FDA in 2015 for the treatment of PAH to delay disease progression and reduce the risk of hospitalization.

                            Brand Name : Uptravi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 30, 2020

                            Lead Product(s) : Selexipag

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Actelion Pharmaceuticals Ltd

                            Switzerland arrow
                            Formnext Forum
                            Not Confirmed

                            Actelion Pharmaceuticals Ltd

                            Switzerland arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Selexipag,Macitentan,Tadalafil

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TRITON Phase 3b Study Results Presented at the European Society of Cardiology Congress

                            Details : While the primary endpoint was not met, exploratory analysis suggests a signal of reduced risk of disease progression of initial triple oral combination therapy vs initial double oral therapy for Pulmonary Arterial Hypertension (PAH) patients .

                            Brand Name : Uptravi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 29, 2020

                            Lead Product(s) : Selexipag,Macitentan,Tadalafil

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth